Sunshine Biopharma (NASDAQ:SBFM) Issues Earnings Results, Misses Estimates By $1.80 EPS

Sunshine Biopharma (NASDAQ:SBFM) announced its quarterly earnings data on Thursday. The company reported ($5.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.40) by ($1.80), FiscalAI reports. The company had revenue of $9.44 million for the quarter, compared to analysts’ expectations of $9.60 million. Sunshine Biopharma had a negative net margin of 17.94% and a negative return on equity of 26.36%.

Sunshine Biopharma Trading Up 3.3%

NASDAQ:SBFM traded up $0.09 on Thursday, reaching $2.84. 51,640 shares of the stock traded hands, compared to its average volume of 115,313. The company has a market capitalization of $613,440.00, a price-to-earnings ratio of -0.01 and a beta of 1.32. Sunshine Biopharma has a 12 month low of $2.53 and a 12 month high of $464.00. The company’s fifty day simple moving average is $10.85 and its 200 day simple moving average is $99.61.

Wall Street Analyst Weigh In

SBFM has been the topic of several analyst reports. Wall Street Zen raised Sunshine Biopharma to a “hold” rating in a report on Saturday, October 31st. Weiss Ratings upgraded Sunshine Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, October 28th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce”.

About Sunshine Biopharma

Sunshine Biopharma, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors. In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations.